New Zealand - English - Medsafe (Medicines Safety Authority)

astrazeneca limited - tixagevimab 100 mg/ml;  ; cilgavimab 100 mg/ml;   - solution for injection - 100 mg/ml - active: tixagevimab 100 mg/ml   excipient: histidine histidine hydrochloride monohydrate polysorbate 80 sucrose water for injection active: cilgavimab 100 mg/ml   excipient: histidine histidine hydrochloride monohydrate polysorbate 80 sucrose water for injection - evusheld is indicated for the pre-exposure prophylaxis of covid-19 in adults and adolescents aged 12 years and older weighing at least 40 kg, - who have moderate to severe immune compromise due to a medical condition or receipt of immunosuppressive medications or treatments that make it likely that they will not mount an adequate immune response to covid-19 vaccination or - for whom vaccination with any approved covid-19 vaccine is not recommended due to a history of severe adverse reaction (e.g., severe allergic reaction) to a covid-19 vaccine(s) and/or covid-19 vaccine component(s).

New Zealand - English - Medsafe (Medicines Safety Authority)

astrazeneca limited - terbutaline sulfate 0.25mg; terbutaline sulfate 200ug equivalent to 0.25 mg metered dose - powder for inhalation - 0.25 mg/dose - active: terbutaline sulfate 0.25mg terbutaline sulfate 200ug equivalent to 0.25 mg metered dose excipient: lactose monohydrate - relief of bronchospasm occurring in bronchial asthma, bronchitis and other bronchopulmonary conditions where bronchospasm is a complicating factor. acute prophylaxis in situations known to induce bronchospasm, e.g. exercise induced asthma.

New Zealand - English - Medsafe (Medicines Safety Authority)

astrazeneca limited - terbutaline sulfate 0.5mg - powder for inhalation - 0.5 mg/dose - active: terbutaline sulfate 0.5mg

New Zealand - English - Medsafe (Medicines Safety Authority)

astrazeneca limited - bicalutamide 150mg - film coated tablet - 150 mg - active: bicalutamide 150mg excipient: hypromellose lactose monohydrate macrogol 300 magnesium stearate povidone purified water   sodium starch glycolate titanium dioxide

New Zealand - English - Medsafe (Medicines Safety Authority)

astrazeneca limited - fulvestrant 50 mg/ml;   - solution for injection - 250 mg/5ml - active: fulvestrant 50 mg/ml   excipient: benzyl alcohol benzyl benzoate castor oil ethanol - faslodex is indicated for the treatment of locally advanced or metastatic breast cancer in postmenopausal women of any age: - not previously treated with endocrine therapy, or - previously treated with endocrine therapy (antioestrogen or aromatase inhibitor) therapy, irrespective of whether their postmenopausal status occurred naturally or was artificially induced.

New Zealand - English - Medsafe (Medicines Safety Authority)

astrazeneca limited - goserelin acetate 11.34mg equivalent to 10.8 mg goserelin;  ; bicalutamide 50mg - combination - 10.8mg+50mg pack - active: goserelin acetate 11.34mg equivalent to 10.8 mg goserelin   excipient: polyglactin active: bicalutamide 50mg excipient: hypromellose lactose macrogol 300 magnesium stearate povidone sodium starch glycolate titanium dioxide - zolacos cp is indicated for the treatment of advanced prostate cancer and prevention of disease flare associated with the use of lhrh agonists.

New Zealand - English - Medsafe (Medicines Safety Authority)

astrazeneca limited - goserelin acetate 3.8mg equivalent to 3.6 mg goserelin;  ; bicalutamide 50mg;   - combination - 3.6mg + 50mg pack - active: goserelin acetate 3.8mg equivalent to 3.6 mg goserelin   excipient: polyglactin active: bicalutamide 50mg   excipient: hypromellose lactose macrogol 300 magnesium stearate povidone sodium starch glycolate titanium dioxide - zolacos cp is indicated for the treatment of advanced prostate cancer and prevention of disease flare associated with the use of lhrh agonists.

New Zealand - English - Medsafe (Medicines Safety Authority)

astrazeneca limited - goserelin acetate 11.34mg equivalent to 10.8 mg goserelin;   - injection (depot) - 10.8 mg - active: goserelin acetate 11.34mg equivalent to 10.8 mg goserelin   excipient: polyglactin - zoladex 10.8 mg is indicated for the management of: 1. prostate cancer suitable for hormonal manipulation.

New Zealand - English - Medsafe (Medicines Safety Authority)

astrazeneca limited - goserelin acetate 3.8mg equivalent to 3.6 mg goserelin;   - injection (depot) - 3.6 mg - active: goserelin acetate 3.8mg equivalent to 3.6 mg goserelin   excipient: polyglactin - zoladex 3.6 mg is indicated for the management of: 1. prostate cancer suitable for hormonal manipulation.

Singapore - English - HSA (Health Sciences Authority)

astrazeneca singapore pte ltd - gefitinib - tablet, film coated - 250 mg - gefitinib 250 mg